The “Hernia Mesh” bucket is no longer a single asset class
January 21, 2026 by Susan Mohr

Mohr Marketing Launches “Post-Settlement” Protocol for Bard Mesh; Opens New Acquisition Channels for Emerging Covidien Litigation

Dual-strategy for 2026: Strict “Tier 1” filtration for mature Bard dockets and aggressive growth focus for Covidien (MDL 3029).

Mohr Marketing, a specialized digital agency for the legal sector, today announced a strategic overhaul of its hernia mesh acquisition programs to align with the shifting mass tort landscape of 2026. The agency is launching a proprietary “Tier 1” Intake Protocol for the mature C.R. Bard litigation (MDL 2846) while simultaneously opening capacity for the emerging Covidien Hernia Mesh docket (MDL 3029).

Following Becton Dickinson’s global settlement framework of approximately $1.9 billion, the Bard litigation has shifted from volume accumulation to strict docket administration. Law firms now face “Lone Pine” style evidentiary standards that require immediate proof of revision.

Optimizing the Mature Asset: Bard (MDL 2846)

Mohr Marketing’s new Bard protocol addresses the “inventory bloat” crisis by utilizing AI WebTracker® technology to pre-qualify claimants. The system is engineered to filter exclusively for “Late Discovery” claimants—patients who had mesh implanted years ago but are only now undergoing revision surgery—ensuring every new asset meets the strict 2026 settlement matrix criteria.

The Strategic Alternative: Covidien (MDL 3029)

Recognizing that firms need growth beyond the winding-down Bard docket, Mohr Marketing is advising partners to pivot acquisition budgets toward In re: Covidien Hernia Mesh Products Liability Litigation (MDL No. 3029).

“The days of ‘sign-and-hold’ are over for Bard; that docket is now about quality and evidence retrieval,” said the Principal of Mohr Marketing. “However, mass tort firms still need growth. That is why we are shifting our aggressive acquisition focus to Covidien. Unlike Bard, the Covidien docket has an active bellwether trial calendar for 2026 and offers a fresh liability theory based on polyester resin degradation. It is the logical ‘next step’ for firms looking to diversify their mesh portfolios.”

Dual-Track Strategy for 2026:

  • For Bard: A “Maintenance Mode” campaign focused on high-value, confirmed revision cases to top off existing inventories.
  • For Covidien: A “Growth Mode” campaign targeting earlier-stage filings to capitalize on the active litigation heat in the District of Massachusetts.

Mohr Marketing is a premier digital acquisition firm specializing in mass tort and class action litigation. By combining proprietary ad-tech with legal intake expertise, Mohr Marketing helps national law firms build compliant, high-value dockets. The agency operates Legal Support Cases, Inc. to provide seamless intake and administrative support for its legal partners.

For more information on the “Tier 1” Bard Protocol or the Covidien Pilot Program, visit [Website URL] or contact the Allentown headquarters.

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, mass tort signed cases, and verified leads can help you achieve your growth goals.

Contact Mohr Marketing today for a custom quote

www.mohrmktg.com 

Best Wishes,
Sue Mohr

Summary
The "Hernia Mesh" bucket is no longer a single asset class.
Article Name
The "Hernia Mesh" bucket is no longer a single asset class.
Description
The agency is launching a proprietary "Tier 1" Intake Protocol for the mature C.R. Bard litigation (MDL 2846) while simultaneously opening capacity for the emerging Covidien Hernia Mesh docket (MDL 3029).
Author
Publisher Name
Mohr Marketing, LLC
Publisher Logo
Spread the love
Secret Link